On Tuesday, markets were mostly red toward the opening bell and many equities fell victim to the global issues troubling the international stock market. Mainly, things like mining stocks and a few energy issuers gained ground. But these weren’t the only stocks making moves higher in October. Many have cited the recent boom in cannabis stocks as a reason to explore other avenues of opportunity but while even that sector sees a pullback, investors are searching for other places for market potential.
Believe it or not, there are stocks focusing on healthcare that have managed to hit new highs this month including Premier Health Group, Inc. (PHGRF)(PHGI.CN), Titan Pharmaceuticals (TTNP), and Amneal Pharmaceuticals Inc. (AMRX).
Premier Health Group, Inc. (PHGRF) (PHGI.CN), has managed to hit trading levels as high as CAD$0.88 this month. The company announced that just this week its common shares that are traded on the OTC Markets Group Inc.’s OTCQB Venture Market in the United States, under the symbol “PHGRF”, are now Depository Trust Company eligible. This was effective October 22, 2018 and allows Premier Health shares to be more easily and economically transferred between brokerage accounts electronically within the United States
Premier Health Group, Inc. (PHGRF)(PHGI.CN)’s subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence. The company currently has an ecosystem of over 100,000 active patients and according to Premier Health, it plans to rapidly increase that number both domestically and internationally.
According to HealthVue, Approximately 15% of Canadians aged 12 and older don’t have a primary care physician. Nearly two-thirds (59%) of seniors are unable to get a same-or next-day appointment. Almost 7 in 10 Canadians avoid seeing a doctor when they are sick. With new access to things like the telemedicine technology that HealthVue offers, the technology allows users to see virtual HealthVue doctor through the telemedicine app/website (Government funded in BC, therefore no additional cost to the patient). Furthermore, prescriptions for users can be electronically submitted to the pharmacy of their choice or delivered free to them by a preferred pharmacy partner.
Titan Pharmaceuticals (TTNP) has seen higher trading volume over the last week. ProNeura™, Titan’s innovative drug delivery platform, is advancing the treatment of select chronic diseases by delivering low-dose, non-fluctuating medication levels for up to one year following a single procedure.
Titan Pharmaceuticals develops proprietary therapeutics for the treatment of select chronic diseases. The company’s lead product is Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction. The U.S. Food and Drug Administration approved Probuphine on May 26, 2016. Probuphine is the first marketed product to provide maintenance treatment of opioid addiction continuously for six months, according to the company.
The company announced this month the appointment of Dane D. Hallberg to the newly created position of Executive Vice President and Chief Commercial Officer, effective immediately. Mr. Hallberg will be responsible for leading all of the company’s commercial activities.
Amneal Pharmaceuticals, Inc. (AMRX) is an integrated specialty pharmaceutical company powered by a U.S. generics business and a growing branded business. Following its recent combination with Impax Laboratories, the company is building a dynamic pharmaceutical company. Amneal’s generics portfolio of approximately 200 generic product families* provides patients with more affordable access to quality medicines.
Earlier this week, Amneal announced that it has received FDA approval for a generic version of Onfi® (clobazam) tablets, 10 mg and 20 mg for oral use, CIV, and Onfi ® (clobazam) oral suspension, 2.5 mg/mL ,CIV.
“Amneal is pleased to receive approval on our clobazam tablets and clobazam oral suspension ANDAs,” said Andy Boyer, Executive Vice President of Commercial Operations for Amneal. “We have immediately initiated commercialization activities for these first-to-market generic products.
Small Cap Reporter is an affiliate of Midam Ventures LLC. Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. MIDAM was hired for a period from 10/1/2018–4/1/2018 to publicly disseminate information about Premier Health Group Inc. Midam was paid $100,000 (CASH) & “500,000” shares of restricted common shares, they own zero shares that were purchased in the open market. Once the (6) six-month restriction is complete on 4/1/2018, Midam plans to sell the “500,000” shares of Premier Health Group Inc. that they hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full Midam disclaimer.